Biotech Values

[DewDiligence]

IDIX – If anyone is not surprised by this news, it would be you: I believe you predicted that the “one-year” NM283 delay announced in June would become a program killer. Well done.

What’s left? Tyzeka, obviously, which is approved in all jurisdictions but is off to a slow start. Also, the HIV and second-generation HCV program (which JP Sommadossi has been mentioning more prominently lately for obvious reasons). And the cash on the balance sheet.

I posted earlier this week that IDIX will be bought out by NVS before the end of 2008 (#msg-21086834). After today’s news, perhaps it will happen sooner.